New life science fund, Mirae Asset Capital Life Science, has launched with $50 million targeted towards U.S. biotechnology companies. The fund, which is part of the Mirae Asset Financial Group, aims to support private biotechs from seed funding to series C. Mirae Asset Capital Life Science is interested in areas such as oncology, immunology, cardiovascular and metabolic diseases, CNS and ophthalmology, and genetic diseases. The fund is also open to using AI and machine learning tools for drug discovery and protein engineering. In addition to its launch, the firm has already led a $75 million series C round for an unnamed oncology company that is developing small molecule precision therapies.
Power Moves: Asian Financial Group Launches $50M US Biotech Fund
Latest from Blog
Arch Venture Partners secures over $3bn for Fund XIII
TLDR: Arch Venture Partners has raised over $3 billion for Fund XIII. Investors in the fund include Alaska Permanent Fund and Rockefeller Brothers Fund. In a recent development, Arch Venture Partners has
Raising Your First Venture Fund: Tips for Success
TLDR: Samir Kaji, a seasoned venture capital professional, shares a six-point plan for raising a venture fund as a first-time fund manager. Key steps include staying focused on a niche, not worrying
Exploring China’s Quantum Computing Breakthrough and VC Trends
TLDR: ONCO stock surged over 80% in pre-market after Altos Venture acquired a stake Chinese low float stocks like DUO rose over 40% in sympathy with large caps Summary: The article discusses
The Blindspot: Venture Capitalists’ Go-To Tool with Fatal Flaw
TLDR: Nader Al-Naji, founder of Bitclout, was arrested for an alleged crypto scam involving VC giant Andreessen Horowitz as a victim. VCs’ pattern matching led them to invest in Al-Naji despite red
Korean startups seek corporate investors in challenging ecosystem climate
TLDR: Korean startups are seeking corporate investors as funding becomes harder to secure. The government in South Korea has relaxed CVC rules to attract more foreign investment. Korean startups are facing a